Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus

Basit Öğe Kaydı
dc.contributor.authorOnmaz, Duygu Eryavuz
dc.contributor.authorTezcan, Dilek
dc.contributor.authorYilmaz, Sema
dc.contributor.authorOnmaz, Mustafa
dc.contributor.authorUnlu, Ali
dc.date.accessioned2024-02-23T13:55:52Z
dc.date.available2024-02-23T13:55:52Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractSystemic lupus erythematosus (SLE) is an autoimmune disease accompanied by increased release of proinflammatory cytokines that are known to activate the indoleamine 2,3-dioxygenase (IDO-1) enzyme, which catalyzes the rate-limiting step of the kynurenine pathway (KP). This study aimed to measure KP metabolite levels in patients with SLE and investigate the relationship between disease activity, clinical findings, and KP. The study included 100 patients with SLE and 100 healthy controls. Serum tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), quinolinic acid (QA) concentrations were measured with tandem mass spectrometry. Serum KYN, KYNA, 3HAA, 3HK, and QA levels of the patients with SLE were significantly higher than the control group. Serum QA levels were elevated in patients with neurological involvement (four patients with peripheral neuropathy and two patients with mononeuropathy), serum KYN levels and KYN/TRP ratio increased in patients with joint involvement, and serum KYN, 3HK, and 3HAA levels and the KYN/TRP ratio were increased in patients with renal involvement. Moreover, KYN and KYN/TRP ratios were positively correlated with the disease activity score. These findings indicated that imbalances in KP metabolites may be associated with the pathogenesis, activation, and clinical manifestations of SLE.en_US
dc.description.sponsorshipThe authors would like to thank the Selcuk University for this study.; Selcuk Universityen_US
dc.description.sponsorshipThe authors would like to thank the Selcuk University for this study.en_US
dc.identifier.doi10.1007/s00726-023-03353-7
dc.identifier.endpage1947en_US
dc.identifier.issn0939-4451
dc.identifier.issn1438-2199
dc.identifier.issue12en_US
dc.identifier.pmid37925676en_US
dc.identifier.scopus2-s2.0-85175866931en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1937en_US
dc.identifier.urihttps://doi.org/10.1007/s00726-023-03353-7
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10996
dc.identifier.volume55en_US
dc.identifier.wosWOS:001094936800001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Wienen_US
dc.relation.ispartofAmino Acidsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCytokinesen_US
dc.subjectInflammationen_US
dc.subjectKynurenine Pathwayen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.subjectTryptophanen_US
dc.titleAltered kynurenine pathway metabolism and association with disease activity in patients with systemic lupusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu